{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:44Z","timestamp":1791407024808,"version":"4.3.3"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There are limited data on the real-world healthcare resource use (HCRU) and management costs of myasthenia gravis (MG) in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aims to assess the burden of disease for patients with MG in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective, observational cohort study of adult patients diagnosed with MG, using data from the Hospital Episode Statistics data warehouse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with a first-ever recorded diagnosis of MG between 30 June 2015 and 30 June 2020 were followed up until 30 June 2021 or death, whichever occurred first. Post-diagnosis patient characteristics, treatment patterns, HCRU, and costs were described. Costs were evaluated using National Health Service reference costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 9087 patients with a median follow-up time of 2.9\u2009years (range, 1.7\u20134.3\u2009years) were included. The mean age at diagnosis was 66.5\u2009years and 53% of the patients were male. A large proportion of patients (72.8%) were admitted as inpatients during follow-up with a mean number of 1.3 admissions. Patients hospitalized for MG-related complications spent a mean of 9.7\u2009days per patient-year in the hospital. During follow-up, 599 (6.6% of the total cohort) and 163 (1.8%) patients had a record of rescue therapy with intravenous immunoglobulin (IVIg) and plasma exchange (PLEX), respectively. Rituximab was administered to 81 (0.9%) patients and 268 (2.9%) patients underwent thymectomy. In those patients receiving rescue therapy or rituximab, &gt;10% received at least three cycles of the same treatment. The average annual cost of hospital admissions across all patients treated with IVIg, PLEX, and rituximab were \u00a3907,072, \u00a3689,979, and \u00a3146,726, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A majority of MG patients required hospitalization or accident and emergency attendance, resulting in high HCRU and costs. A subset of patients required rescue therapy (including IVIg and PLEX), rituximab administration, ventilation, or thymectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864241237495","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T01:27:55Z","timestamp":1713317275000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-7750","authenticated-orcid":false,"given":"Jordy","family":"van Enkhuizen","sequence":"first","affiliation":[{"name":"UCB Pharma, 216 Bath Road, Slough, Berkshire SL1 3WE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Binns","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Betts","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Saberi","family":"Hosnijeh","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Modelling and Meta-Analysis, OPEN Health, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Alexander","sequence":"additional","affiliation":[{"name":"Real-World Evidence, OPEN Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McCormack","sequence":"additional","affiliation":[{"name":"Real-World Evidence, OPEN Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Rare Diseases, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"bibr1-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002"},{"key":"bibr2-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000596"},{"key":"bibr3-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261983"},{"key":"bibr4-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"bibr5-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217"},{"key":"bibr6-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13503"},{"key":"bibr7-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"bibr8-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00912-8"},{"key":"bibr9-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1592180"},{"key":"bibr10-17562864241237495","unstructured":"National Health Service. Hospital episode statistics (HES). NHS England. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics (2023, accessed September 2023)."},{"key":"bibr11-17562864241237495","unstructured":"National Health Service. National cost collection for the NHS. NHS England. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/ (2020, Accessed September 2023)."},{"key":"bibr12-17562864241237495","unstructured":"National Health Service. A simple guide to payment by results. NHS England. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213150\/PbR-Simple-Guide-FINAL.pdf (2012, Accessed September 2023)."},{"key":"bibr13-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"bibr14-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"bibr15-17562864241237495","unstructured":"National Health Service. About the summary hospital-level mortality indicator (SHMI). NHS England. https:\/\/digital.nhs.uk\/data-and-information\/publications\/ci-hub\/summary-hospital-level-mortality-indicator-shmi (2023, accessed September 2023)."},{"key":"bibr16-17562864241237495","unstructured":"National Health Service. High-cost drugs commissioning list. NHS England. https:\/\/www.england.nhs.uk\/publication\/nhs-england-drugs-list\/ (2023, accessed September 2023)."},{"key":"bibr17-17562864241237495","unstructured":"Office for National Statistics. Population and household estimates, England and Wales: census 2021, unrounded data. GOV.UK. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/populationandhouseholdestimatesenglandandwales\/census2021unroundeddata (2021, accessed September 2023)."},{"key":"bibr18-17562864241237495","unstructured":"National Health Service. Disclosure control methodology for Hospital Episode Statistics (HES) and Emergency Care Data Set (ECDS). NHS England. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\/disclosure-control-methodology-for-hospital-episode-statistics-and-emergency-care-data-set (2018, accessed September 2023)."},{"key":"bibr19-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.02.002"},{"key":"bibr20-17562864241237495","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999"},{"key":"bibr21-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.629"},{"key":"bibr22-17562864241237495","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604"},{"key":"bibr23-17562864241237495","unstructured":"National Health Service. Immunoglobulin database: annual report 2021\/2022. NHS England. https:\/\/igd.mdsas.com\/wp-content\/uploads\/Igd_DataReport_202122.pdf (2023, accessed September 2023)."},{"key":"bibr24-17562864241237495","unstructured":"National Institute for Health and Care Excellence. British National Formulary (BNF). NICE. https:\/\/www.nice.org.uk\/drugs\/normal-immunoglobulin\/medicinal-forms\/ (2023, accessed September 2023)."},{"key":"bibr25-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08210-z"},{"key":"bibr26-17562864241237495","unstructured":"National Health Service, England. Clinical commissioning policy statement: rituximab bio-similar for the treatment of myasthenia gravis (adults). Version 2; Reference: 170084P. NHS England. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/04\/Rituximab-biosimilar-for-the-treatment-of-myasthenia-gravis-adults-v2.pdf (2021, accessed September 2023)."},{"key":"bibr27-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851"},{"key":"bibr28-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02692-4"},{"key":"bibr29-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221150327"},{"key":"bibr30-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22327"},{"key":"bibr31-17562864241237495","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120531"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241237495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864241237495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241237495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:27:34Z","timestamp":1738034854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864241237495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["10.1177\/17562864241237495"],"URL":"https:\/\/doi.org\/10.1177\/17562864241237495","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17562864241237495"}}